94 unknown, 46 recruiting, 25 completed, 19 not yet recruiting. 56 Not applicable, 43 Phase 2, 25 Early Phase 1, 23 Phase 4, 13 Phase 1.
Follow Shanghai Changzheng Hospital: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Hyperthermic Intraperitoneal Chemotherapy, Serplulimab, S-1 - Locally Advanced Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 48 | 2026-07-13 | 2026-10-22 |
| Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance Hemodialysis Nalfurafine Hydrochloride, Basic treatment - Chronic Kidney Disease-Associated Pruritus in Hemodialysis | Not applicable | Not yet recruiting | Chinese PLA General Hospital | 150 | 2026-07-01 | 2026-06-16 |
| KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE - POEMS Syndrome | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 20 | 2026-06-15 | 2026-06-17 |
| Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases Metastatic Spinal Tumors, Spinal Cord Compression | Not yet recruiting | Shanghai Changzheng Hospital | 150 | 2026-05-01 | 2026-04-14 | |
| MTS109 in Patients With Refractory Autoimmune Diseases MTS109 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 15 | 2026-03-24 | 2026-06-30 |
| Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding Portal Hypertension, Gastroesophageal Varices Hemorrhage | Not yet recruiting | Shanghai Zhongshan Hospital | 1066 | 2026-03-17 | 2026-03-31 | |
| AI-Powered Precision Decision-Making for Pancreatic Diseases Diagnosis by Artificial Intelligence model - Pancreatic Cancer, Diagnose Disease | Recruiting | Changhai Hospital | 2000 | 2026-03-01 | 2026-02-27 | |
| Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer anlotinib and sintilimab - Colorectal Cancer | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 37 | 2026-02-24 | 2026-02-09 |
| A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease. Diagnostic tear fluid collection and ocular surface evaluation - Dry Eye Disease, Iron | Recruiting | Shanghai Changzheng Hospital | 52 | 2026-02-06 | 2026-02-10 | |
| Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer Standard Endocrine Therapy, LC-K76 - mHSPC, mHNPC | Early Phase 1 | Not yet recruiting | Shanghai Changzheng Hospital | 40 | 2026-02-01 | 2026-02-05 |
| Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) LC-K76, Tislelizumab, Standard Androgen Deprivation Therapy (ADT) - mCRPC | Early Phase 1 | Not yet recruiting | Shanghai Changzheng Hospital | 10 | 2026-02-01 | 2026-02-05 |
| Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy Non-invasive Eye Tracking Assessment - Thyroid Associated Ophthalmopathies, Eye Tracking | Recruiting | Shanghai Changzheng Hospital | 100 | 2026-01-31 | 2026-02-06 | |
| Efficacy and Safety of Rifaximin-α in Treating MASLD Rifaximin-α (Alfa Wassermann S.p.A., Italy) - Metabolic Dysfunction-Associated Steatotic Liver Disease | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 60 | 2026-01-15 | 2026-02-02 |
| Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study MRI scan，ocular ultrasound - Graves Ophthalmopathy, Graves Disease | Recruiting | Shanghai Changzheng Hospital | 1200 | 2026-01-01 | 2026-07-21 | |
| Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC) routines - Glottic Carcinoma, Supraglottic Carcinoma | Recruiting | Eye & ENT Hospital of Fudan University | 1000 | 2025-12-01 | 2025-12-04 | |
| Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer Quantum Detection - Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis) | Not yet recruiting | Shanghai Changzheng Hospital | 1100 | 2025-12-01 | 2025-11-20 | |
| A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases GT801 Injection - Moderate to Severe Refractory Autoimmune Disease | Early Phase 1 | Recruiting | Grit Biotechnology | 22 | 2025-11-07 | 2026-05-27 |
| Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer Postbiotics, 2.5 g per dose, three times per day, Placebo, 2.5 g per dose, three times per day - Cachexia; Cancer | Not applicable | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 150 | 2025-11-01 | 2025-09-25 |
| Observational Study of Sacral Nerve Function After Sacral Tumor Resection Sacral Tumors | Not yet recruiting | Shanghai Changzheng Hospital | 400 | 2025-08-01 | 2025-08-06 | |
| Evaluation of the Efficacy and Safety of Absorbable vs Traditional Bone Wax for Facet Fusion After Lumbar Fusion Surgery Absorbable bone wax for hemostasis in the osteotomy surface of the facet joint, Traditional bone wax for hemostasis in the osteotomy surface of the facet joint - Lumbar Fusion Surgery, Fusion of Joint | Not applicable | Not yet recruiting | Shanghai Changzheng Hospital | 330 | 2025-07-01 | 2025-06-27 |
Showing 20 of 203. Sign in to see all of them.
Multiple Myeloma (20) · Colorectal Neoplasms (13) · Diabetes Mellitus (10) · Hypertension, Portal (9) · Graves Ophthalmopathy (7) · Prostatic Neoplasms (6) · Fibrosis (5) · Neoplasms (5) · Pancreatic Neoplasms (5) · Recurrence (5) · Carcinoma, Hepatocellular (4) · Carcinoma, Non-Small-Cell Lung (4) · Disease (4) · Insulin-Like Growth Factor I, Resistance To (4) · Lupus Erythematosus, Systemic (4)
Oxaliplatin (6) · Capecitabine (5) · Cyclophosphamide (5) · tislelizumab (5) · Bevacizumab (4) · Carvedilol (4) · Dexamethasone (4) · Rifaximin (4) · alverine (4) · anlotinib (4) · Bortezomib (3) · Gemcitabine (3) · Glucocorticoids (3) · Methylprednisolone (3) · Surgical Procedures, Operative (3)
China (176)
Wei-Fen Xie, M.D. (5) · Wei-Fen Xie, MD (5) · Hao Yin (4) · Xuhua Lu, M.D. (4) · Huji Xu, Ph.D, MD (3) · Jian Shi, MD (3) · Juan Du, Doctor (3) · Juan Du, MD (3) · Lijun Hou, MD,PhD (3) · Bin Shi, MD (2) · Changlin Mei (2) · Changlin Mei, MD (2) · Changlin Mei, master (2) · Fu-Sheng Wang, MD, PhD (2) · Haiyang Zhou, MD (2)
PMID 26256457, PMID 29122701, PMID 30958370, PMID 31235344, PMID 31914229, PMID 31937364, PMID 32881347, PMID 36850008, PMID 37365538, PMID 37467180, PMID 10613747, PMID 11294711, PMID 11342888, PMID 14565873, PMID 14722039, PMID 15108734, PMID 15221572, PMID 15365071, PMID 15470215, PMID 15851849, PMID 15985009, PMID 16112300, PMID 16636023, PMID 16916581, PMID 17645714, PMID 17889125, PMID 18196435, PMID 18445230, PMID 18819060, PMID 18955183, PMID 19034057, PMID 19085366, PMID 19111391, PMID 19220668, PMID 19233676, PMID 19347838, PMID 19459814, PMID 19502970, PMID 19857686, PMID 19891819, PMID 19910449, PMID 20041484, PMID 20051942, PMID 20101593, PMID 20149237, PMID 20880607, PMID 20930266, PMID 20968209, PMID 21052986, PMID 21118724